CL2011002209A1 - Compuestos derivados de 2-mercaptoquinolin-3-carboxamida; medicamento que los comprende; y uso para tratar el dolor, epilepsia, incontinencia urinaria, ansiedad, dependencia manias, transtornos bipolares, migraña, enfermedades cognitivas, discinesia asociada a la distonia y/o incontinencia urinaria. - Google Patents
Compuestos derivados de 2-mercaptoquinolin-3-carboxamida; medicamento que los comprende; y uso para tratar el dolor, epilepsia, incontinencia urinaria, ansiedad, dependencia manias, transtornos bipolares, migraña, enfermedades cognitivas, discinesia asociada a la distonia y/o incontinencia urinaria.Info
- Publication number
- CL2011002209A1 CL2011002209A1 CL2011002209A CL2011002209A CL2011002209A1 CL 2011002209 A1 CL2011002209 A1 CL 2011002209A1 CL 2011002209 A CL2011002209 A CL 2011002209A CL 2011002209 A CL2011002209 A CL 2011002209A CL 2011002209 A1 CL2011002209 A1 CL 2011002209A1
- Authority
- CL
- Chile
- Prior art keywords
- urinary incontinence
- mercaptoquinoline
- epilepsy
- carboxamide
- anxiety
- Prior art date
Links
- 206010046543 Urinary incontinence Diseases 0.000 title abstract 3
- CKWKREFECQVBBZ-UHFFFAOYSA-N 2-sulfanylidene-1h-quinoline-3-carboxamide Chemical compound C1=CC=C2N=C(S)C(C(=O)N)=CC2=C1 CKWKREFECQVBBZ-UHFFFAOYSA-N 0.000 title abstract 2
- 208000019901 Anxiety disease Diseases 0.000 title abstract 2
- 208000002193 Pain Diseases 0.000 title abstract 2
- 230000036506 anxiety Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 206010015037 epilepsy Diseases 0.000 title abstract 2
- 208000020925 Bipolar disease Diseases 0.000 title 1
- 208000012661 Dyskinesia Diseases 0.000 title 1
- 208000014094 Dystonic disease Diseases 0.000 title 1
- 206010026749 Mania Diseases 0.000 title 1
- 208000019695 Migraine disease Diseases 0.000 title 1
- 208000010877 cognitive disease Diseases 0.000 title 1
- 208000010118 dystonia Diseases 0.000 title 1
- 206010027599 migraine Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09003597 | 2009-03-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2011002209A1 true CL2011002209A1 (es) | 2012-02-10 |
Family
ID=40671387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2011002209A CL2011002209A1 (es) | 2009-03-12 | 2011-09-08 | Compuestos derivados de 2-mercaptoquinolin-3-carboxamida; medicamento que los comprende; y uso para tratar el dolor, epilepsia, incontinencia urinaria, ansiedad, dependencia manias, transtornos bipolares, migraña, enfermedades cognitivas, discinesia asociada a la distonia y/o incontinencia urinaria. |
Country Status (20)
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3178067B2 (ja) | 1991-02-26 | 2001-06-18 | ぺんてる株式会社 | スズ−ニッケル二元合金電気めっき液組成物 |
| TWI504395B (zh) * | 2009-03-10 | 2015-10-21 | Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier | |
| BRPI1009428A2 (pt) * | 2009-03-10 | 2016-03-01 | Gruenenthal Gmbh | 3-aminoisoxazolopiridina substituída como moduladores de kcnq2/3 |
| TWI475020B (zh) | 2009-03-12 | 2015-03-01 | The substituted nicotine amide as a KCNQ2 / 3 modifier | |
| TW201038565A (en) | 2009-03-12 | 2010-11-01 | Gruenenthal Gmbh | Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators |
| PT2609086E (pt) | 2010-08-27 | 2015-06-30 | Gruenenthal Gmbh | 2-oxo- e 2-tioxo-di-hidroquinolina-3-carboxamidas substituídas como moduladores de kcnq2/3 |
| JP5837933B2 (ja) * | 2010-08-27 | 2015-12-24 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Ｋｃｎｑ２／３調節因子としての置換された２−オキシ−キノリン−３−カルボキサミド |
| MX2013002295A (es) | 2010-09-01 | 2013-05-09 | Gruenenthal Gmbh | 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. |
| US9775843B2 (en) | 2012-10-11 | 2017-10-03 | Grünenthal GmbH | Treatment and/or prophylaxis of TSPO mediated diseases and/or disorders |
| US9248122B2 (en) | 2012-11-28 | 2016-02-02 | Grünenthal GmbH | Heteroquinoline-3-carboxamides as KCNQ2/3 modulators |
| CA2892652A1 (en) | 2012-11-28 | 2014-06-05 | Grunenthal Gmbh | Heteroquinoline-3-carboxamides as kcnq2/3 modulators |
| EP2951156A1 (en) | 2012-11-28 | 2015-12-09 | Grünenthal GmbH | Specific carboxamides as kcnq2/3 modulators |
| AU2014212426B8 (en) * | 2013-01-31 | 2018-05-10 | Vertex Pharmaceuticals Incorporated | Quinoline and Quinoxaline Amides as Modulators of Sodium Channels |
| EP2951153B1 (en) | 2013-02-01 | 2019-04-03 | Regenacy Pharmaceuticals, LLC | Selective hdac3 inhibitors |
| US9139583B2 (en) | 2013-02-01 | 2015-09-22 | Acetylon Pharmaceuticals, Inc. | Selective HDAC3 inhibitors |
| HK1217092A1 (zh) | 2013-02-15 | 2016-12-23 | Kala Pharmaceuticals, Inc. | 治疗性化合物及其用途 |
| ES2831625T3 (es) | 2013-02-20 | 2021-06-09 | Kala Pharmaceuticals Inc | Compuestos terapéuticos y sus usos |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| US9458169B2 (en) | 2013-11-01 | 2016-10-04 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| PH12015000236B1 (en) * | 2015-07-06 | 2024-01-10 | Samsung Electronics Co Ltd | Electronic device for providing a calibrated keyboard configuration |
| AU2017324713B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| US10392399B2 (en) | 2016-09-08 | 2019-08-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| US10336767B2 (en) | 2016-09-08 | 2019-07-02 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| WO2018110669A1 (en) | 2016-12-15 | 2018-06-21 | Ono Pharmaceutical Co., Ltd. | Activator of trek (twik related k+ channels) channels |
| DE102018212006B3 (de) | 2018-07-18 | 2019-10-31 | Universität Greifswald | Thioether als Modulatoren von Kv7.2/Kv7.3-Kanälen |
| EP4580618A2 (en) * | 2022-08-30 | 2025-07-09 | Pannex Therapeutics Inc. | Pannexin-1 modulators and methods of treating disorders in which pannexin-1 is implicated |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2706977A1 (de) | 1977-02-18 | 1978-08-24 | Hoechst Ag | Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung |
| FR2532939A1 (fr) * | 1982-09-13 | 1984-03-16 | Roussel Uclaf | Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur preparation, leur application comme medicament, les compositions les renfermant et les nouveaux intermediaires obtenus |
| DE4032147A1 (de) | 1990-10-10 | 1992-04-16 | Bayer Ag | Verwendung von substituierten 2-mercaptonicotinsaeurederivaten zur bekaempfung von endoparasiten, neue substituierte 2-mercaptonicotinsaeurederivate und verfahren zu ihrer herstellung |
| EP0716077A1 (de) | 1994-12-08 | 1996-06-12 | Ciba-Geigy Ag | Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren |
| WO1996026925A1 (en) | 1995-03-01 | 1996-09-06 | Banyu Pharmaceutical Co., Ltd. | Arylthioacetamide derivatives |
| DE19738616A1 (de) * | 1997-09-04 | 1999-03-11 | Clariant Gmbh | 4-Hydroxychinolin-3-carbonsäure-Derivate als Lichtschutzmittel |
| DE19738615A1 (de) * | 1997-09-04 | 1999-03-11 | Clariant Gmbh | Neue Lichtschutzmittel auf Basis von sterisch gehinderten Aminen |
| AU3033500A (en) * | 1999-01-15 | 2000-08-01 | Agouron Pharmaceuticals, Inc. | Non-peptide glp-1 agonists |
| JP2003506387A (ja) | 1999-08-04 | 2003-02-18 | アイカゲン インコーポレイテッド | カリウムチャンネルオープナーとしてのベンズアニリド |
| JP2003506388A (ja) | 1999-08-04 | 2003-02-18 | アイカゲン インコーポレイテッド | 疼痛および不安症を処置または予防するための方法 |
| CA2438231A1 (en) | 2001-02-20 | 2002-08-29 | Gene G. Kinney | 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators |
| WO2002072088A2 (en) * | 2001-02-20 | 2002-09-19 | Bristol-Myers Squibb Company | Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases |
| US6593349B2 (en) | 2001-03-19 | 2003-07-15 | Icagen, Inc. | Bisarylamines as potassium channel openers |
| EP1372654A4 (en) * | 2001-04-06 | 2007-10-03 | Smithkline Beecham Corp | QUINOLINE INHIBITORS OF HYAK1 AND HYAK3 KINASES |
| EP1542966A1 (en) | 2002-09-17 | 2005-06-22 | Pharmacia Corporation | Aromatic liver x-receptor modulators |
| CA2505195C (en) | 2002-12-23 | 2012-07-10 | Icagen, Inc. | Quinazolinones as potassium channel modulators |
| EP1449841A1 (en) | 2003-02-19 | 2004-08-25 | Bayer CropScience SA | New fungicidal compounds |
| WO2005035514A2 (en) | 2003-10-08 | 2005-04-21 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups |
| ES2327760T3 (es) | 2004-05-04 | 2009-11-03 | Raqualia Pharma Inc | Compuestos de aril-heteroaril-amida ortosustituidos. |
| ME02799B (me) * | 2004-06-24 | 2018-01-20 | Vertex Pharma | Modulatori ATP-vezujućih kasetnih transportera |
| EP1814856A1 (en) | 2004-11-12 | 2007-08-08 | Galapagos N.V. | Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes |
| MX2007010547A (es) | 2005-03-03 | 2007-10-03 | Lundbeck & Co As H | Derivados de piridina sustituidos. |
| DE102005038947A1 (de) | 2005-05-18 | 2006-11-30 | Grünenthal GmbH | Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln |
| ATE432259T1 (de) | 2005-07-20 | 2009-06-15 | Lilly Co Eli | Pyridinderivate als dipeptedyl-peptidase-hemmer |
| US7915410B2 (en) | 2005-09-09 | 2011-03-29 | Bristol-Myers Squibb Company | Acyclic IKur inhibitors |
| JP2009515934A (ja) | 2005-11-18 | 2009-04-16 | ノイロサーチ アクティーゼルスカブ | 新規なキナゾリン誘導体及びこれらの医学的使用 |
| EP2069020B1 (en) | 2006-07-20 | 2010-01-27 | Amgen Inc. | Benzo[d]isoxazole derivatives as c-kit tyrosine kinase inhibitors for the treatment of disorders associated with the over production of histamine |
| AU2007275683B2 (en) | 2006-07-20 | 2012-05-10 | Amgen Inc. | Di-amino-substituted heterocyclic compounds and methods of use |
| US20100022589A1 (en) | 2006-07-27 | 2010-01-28 | Mccoull William | Pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase |
| DE102006049452A1 (de) | 2006-10-17 | 2008-05-08 | Grünenthal GmbH | Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln |
| ATE538084T1 (de) * | 2006-11-28 | 2012-01-15 | Valeant Pharmaceuticals Int | Bicyclische 1,4-retigabin-analoga als kaliumkanalhemmer |
| US8563566B2 (en) | 2007-08-01 | 2013-10-22 | Valeant Pharmaceuticals International | Naphthyridine derivatives as potassium channel modulators |
| JP5341084B2 (ja) | 2007-08-03 | 2013-11-13 | エフ．ホフマン−ラ ロシュ アーゲー | Ｔａａｒ１リガンドとしてのピリジンカルボキシアミド及びベンズアミド誘導体 |
| CA2702469A1 (en) | 2007-10-19 | 2009-04-23 | Boehringer Ingelheim International Gmbh | Ccr10 antagonists |
| TWI504395B (zh) * | 2009-03-10 | 2015-10-21 | Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier | |
| BRPI1009428A2 (pt) * | 2009-03-10 | 2016-03-01 | Gruenenthal Gmbh | 3-aminoisoxazolopiridina substituída como moduladores de kcnq2/3 |
| TW201038565A (en) * | 2009-03-12 | 2010-11-01 | Gruenenthal Gmbh | Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators |
| TWI475020B (zh) * | 2009-03-12 | 2015-03-01 | The substituted nicotine amide as a KCNQ2 / 3 modifier |
-
2010
- 2010-02-24 TW TW099105238A patent/TWI461197B/zh not_active IP Right Cessation
- 2010-03-10 US US12/720,864 patent/US20100234372A1/en not_active Abandoned
- 2010-03-11 MX MX2011009369A patent/MX2011009369A/es active IP Right Grant
- 2010-03-11 JP JP2011553352A patent/JP5727946B2/ja not_active Expired - Fee Related
- 2010-03-11 CN CN2010800112967A patent/CN102348692A/zh active Pending
- 2010-03-11 BR BRPI1008939A patent/BRPI1008939A2/pt not_active IP Right Cessation
- 2010-03-11 EP EP10708726A patent/EP2406229A1/de not_active Withdrawn
- 2010-03-11 NZ NZ595625A patent/NZ595625A/xx not_active IP Right Cessation
- 2010-03-11 RU RU2011141188/04A patent/RU2011141188A/ru not_active Application Discontinuation
- 2010-03-11 AU AU2010223513A patent/AU2010223513B2/en not_active Ceased
- 2010-03-11 CA CA2755004A patent/CA2755004A1/en not_active Abandoned
- 2010-03-11 KR KR1020117023788A patent/KR20110132590A/ko not_active Withdrawn
- 2010-03-11 WO PCT/EP2010/001509 patent/WO2010102811A1/de not_active Ceased
- 2010-03-11 PE PE2011001567A patent/PE20120790A1/es not_active Application Discontinuation
- 2010-03-12 AR ARP100100777A patent/AR075824A1/es not_active Application Discontinuation
-
2011
- 2011-08-24 CO CO11107978A patent/CO6410292A2/es not_active Application Discontinuation
- 2011-09-04 IL IL214945A patent/IL214945A0/en unknown
- 2011-09-08 CL CL2011002209A patent/CL2011002209A1/es unknown
- 2011-09-23 EC EC2011011348A patent/ECSP11011348A/es unknown
- 2011-10-11 ZA ZA2011/07444A patent/ZA201107444B/en unknown
-
2012
- 2012-06-15 US US13/523,955 patent/US8399673B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AR075824A1 (es) | 2011-04-27 |
| TW201034670A (en) | 2010-10-01 |
| US20100234372A1 (en) | 2010-09-16 |
| BRPI1008939A2 (pt) | 2016-03-15 |
| MX2011009369A (es) | 2011-09-27 |
| PE20120790A1 (es) | 2012-07-08 |
| JP2012520249A (ja) | 2012-09-06 |
| CO6410292A2 (es) | 2012-03-30 |
| US20120252841A1 (en) | 2012-10-04 |
| NZ595625A (en) | 2012-10-26 |
| IL214945A0 (en) | 2011-11-30 |
| CA2755004A1 (en) | 2010-09-16 |
| AU2010223513B2 (en) | 2014-12-04 |
| US8399673B2 (en) | 2013-03-19 |
| ZA201107444B (en) | 2012-06-27 |
| ECSP11011348A (es) | 2011-10-31 |
| KR20110132590A (ko) | 2011-12-08 |
| RU2011141188A (ru) | 2013-04-20 |
| CN102348692A (zh) | 2012-02-08 |
| EP2406229A1 (de) | 2012-01-18 |
| WO2010102811A1 (de) | 2010-09-16 |
| JP5727946B2 (ja) | 2015-06-03 |
| TWI461197B (zh) | 2014-11-21 |
| AU2010223513A1 (en) | 2011-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2011002209A1 (es) | Compuestos derivados de 2-mercaptoquinolin-3-carboxamida; medicamento que los comprende; y uso para tratar el dolor, epilepsia, incontinencia urinaria, ansiedad, dependencia manias, transtornos bipolares, migraña, enfermedades cognitivas, discinesia asociada a la distonia y/o incontinencia urinaria. | |
| MX2019008337A (es) | Uso de cannabinoides para el tratamiento de epilepsia. | |
| MX351028B (es) | Determinadadas entidades, composiciones y metodos quimicos. | |
| BR112013021509A2 (pt) | composições para cuidado pessoal | |
| MX2020006951A (es) | Uso de cannabinoides en el tratamiento de epilepsia. | |
| NI201000044A (es) | Bromhidrato de bupropión y aplicaciones terapéuticas | |
| GT201400222A (es) | Agentes para tratar trastornos que implican la modulación de receptores de rianodina | |
| ECSP099502A (es) | 4-fenil-piran-3,5-dionas, 4-fenil-tiopiran-3,5-dionas y ciclohexantrionas como nuevos herbicidas | |
| CL2009000393A1 (es) | Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular. | |
| MX2015003140A (es) | Formulaciones de enzalutamida. | |
| CL2011002160A1 (es) | Compuestos derivados de 3-amino-2-mercaptoquinolinas sustituidas; composicion farmaceutica que contiene dichos compuestos; y su uso para tratar dolor, epilepsis, incontinencia urinaria, manias, migraña, trastornos bipolares, enfermedades cognitivas, discinesia asociada a la distonia y/o incontinencia urinaria. | |
| GT200900230A (es) | 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso | |
| CL2012001714A1 (es) | Compuestos derivados de pirrol[3.4-b]piridin-5-ona, inhibidores de pi3k; composicion farmaceutica que los comprende; y uso para el tratamiento de enfermedades tales como alzheimer, epilepsia, esclerosis multiple, parkinson, entre otras. | |
| NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
| CR20160222U (es) | Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas | |
| ECSP12011720A (es) | Compuestos heterocíclicos y usos de los mismos | |
| SV2010003593A (es) | Nuevos herbicidas | |
| CL2014003225A1 (es) | Composición que comprende un agente de control biológico y un fungicida. | |
| CL2012001031A1 (es) | Compuestos derivados de 2-oxo-1-pirrolidinil-imidazotiadiazol; composición farmacéutica que los comprende; útiles para el tratamiento de la epilepsia, transtornos neurológicos, entre otros. | |
| BR112012032008A2 (pt) | anticorpos s100a4 e usos terapêuticos do mesmo | |
| NI201000015A (es) | Bromhidrato de bupropión y aplicaciones terapéuticas | |
| BR112013025777A2 (pt) | imidazopiridazinas como inibidores da quinase akt | |
| UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
| CR20160290A (es) | Inhibidores tetracíclicos de autotaxina | |
| MX2015012444A (es) | Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos. |